Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy in several indications owing to their favourable balance between efficacy and tolerability. Trastuzumab deruxtecan exemplifies this paradigm shift, having achieved regulatory approvals across multiple HER2 (ERBB2)-expressing or HER2-mutated solid tumours, including breast, gastric, and non-small-cell lung cancers (NSCLCs).
Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy in several indications owing to their favourable balance between efficacy and tolerability. Trastuzumab deruxtecan exemplifies this paradigm shift, having achieved regulatory approvals across multiple HER2 (ERBB2)-expressing or HER2-mutated solid tumours, including breast, gastric, and non-small-cell lung cancers (NSCLCs).